China Pharma to Launch Highly Purified NMN+PQQ Product

10 June 2021 | Thursday | News

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.

NMN is a natural compound found in the human body and is constantly being metabolized. It is also found in trace amounts in certain foods. NMN serves as a precursor to NAD+, which is a coenzyme found in all living cells, and is required for the body's core biological processes, including the human body's energy production, metabolism, and gene expression.

Fortunately, NAD+ levels, which naturally decline with age, can be replenished by with NMN supplements. Potential benefits of restoring NAD+ levels include slowing the adverse impacts of aging, support for an improved cardiovascular function, and aiding wellness, a healthy weight management regimen and endurance.

Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "We are gearing up to launch a highly purified NMN+PQQ product given the success of our recent pilot test and high market demand. We expect to leverage China Pharma's proven track record of providing superior ingredients to ensure that customers are buying a high-quality, pure NMN food supplement whenever they see our brand. We see NMN+PQQ as a natural fit for our comprehensive healthcare category, which is an ideal non-medicine therapy; and a new star for our portfolio, which already boasts 20 branded and generic drugs, giving us added revenue stability, visibility and the product pipeline needed to support the Company's continued growth. We plan to leverage the preferential policies of Hainan Free Trade Port to sell this product. We will later consider partnering to accelerate sales worldwide. Overall, this is an exciting development for China Pharma, which opens considerable new, multi-year growth opportunities to us."

This press release is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not rely upon this information for self-diagnosis or for self-treatment of a health problem or disease. You should contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding food, health, wellness and dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition nor is this product intended to diagnose, treat, cure or prevent diseases.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in